Cargando…
Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn's Disease
Biological agents are frequently used in the management of inflammatory bowel disease, and it is important to understand the potential adverse effects of these therapies. Ustekinumab is a human monoclonal antibody that interferes with interleukin-12 and -23 cytokine signaling and is approved for the...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
S. Karger AG
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167711/ https://www.ncbi.nlm.nih.gov/pubmed/30283287 http://dx.doi.org/10.1159/000492462 |